Comparable immunogenicity between different etanercept biosimilars
| Samsung Benepali (SB4)26 | Sandoz Erelzi (GP2015)27* | Coherus (CHS0214)28 | ||||
| SB4 | Enbrel | GP2015 | Enbrel | CHS0214 | Enbrel | |
| ADA + (Week 8) | 2 (0.7%) | 38 (12.8%) | 0 | 5 (1.9%) | X | X |
| ADA + (Week 24) | 2 (0.7%) | 39 (13.2%) | 0 | 5 (1.9%) | 1.3% | 4.7% |
| ADA + (Week 52) | 3 (1.0%) | 39 (13.2%) | 0 | 5 (1.9%) | X | X |
| nAb + (Week 8) | 0 | 1 | 0 | 0 | X | X |
| nAb + (Week 24) | 0 | 1 | 0 | 0 | 0 | 0 |
| nAb + (Week 52) | 0 | 1 | 0 | 0 | X | X |
X means not stated. *Data for study 302 in patients with psoriasis. ADA, anti drug antibody; nAb, neutralising antibody.